Sign inCreate account

Report workspace tools

NCT00785785COMPLETEDanonymous

A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

Sponsor

Source record

Novartis Pharmaceuticals

Phase

Source record

Phase III

Modality

AI-normalized

small molecule

Target

AI-normalized

Gastrointestinal Stromal Tumors (GIST)

Indication / condition

AI-normalized

Gastrointestinal Stromal Tumor (GIST)

Intervention

Source record

Nilotinib (AMN107), imatinib (STI571)

Source & freshness

Source record

NCT ID

NCT00785785

Original source

ClinicalTrials.gov

Source last updated

Jun 16, 2016

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00785785

Title

A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

Sponsor

Novartis Pharmaceuticals

Status

COMPLETED

Phase

Phase III

Condition raw

Gastrointestinal Stromal Tumor (GIST)

Condition normalized

Gastrointestinal Stromal Tumor (GIST)

Modality raw

Gastrointestinal Stromal Tumor (GIST)

Modality normalized

small molecule

Target raw

Gastrointestinal Stromal Tumors (GIST)

Target normalized

Gastrointestinal Stromal Tumors (GIST)

Interventions

Nilotinib (AMN107), imatinib (STI571)

Public preview

Source record

This clinical trial evaluated the efficacy and safety of nilotinib compared to imatinib in adult patients with unresectable or metastatic GIST. Conducted by Novartis, the study involved 644 participants across multiple sites and aimed to determine the time to progression-free survival (PFS) as the primary outcome.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00785785

Status

COMPLETED

Phase

Phase III

Sponsor

Novartis Pharmaceuticals

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the efficacy and safety of nilotinib compared to imatinib in adult patients with unresectable or metastatic GIST. Conducted by Novartis, the study involved 644 participants across multiple sites and aimed to determine the time to progression-free survival (PFS) as the primary outcome.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 16, 2016
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00785785

Indication

Gastrointestinal Stromal Tumor (GIST)

Modality

small molecule

Target

Gastrointestinal Stromal Tumors (GIST)

Intervention

Nilotinib (AMN107), imatinib (STI571)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.